Patents by Inventor Junge Zhang
Junge Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11937751Abstract: The present disclosure provides a movable electric device. The movable electric device includes a movable device body and a contact detection electrode. The movable device body has an electric drive means. The contact detection electrode is mounted on the movable device body. When the contact detection electrode _contacts diffusible dirt, a resistance, capacitance or impedance of the contact detection electrode varies.Type: GrantFiled: November 9, 2018Date of Patent: March 26, 2024Assignees: GUANGDONG MIDEA WHITE HOME APPLIANCE TECHNOLOGY INNOVATION CENTER CO., LTD., MIDEA GROUP CO., LTD.Inventors: Pin Yang, Jiefeng Cheng, Xinjian Huang, Shuyun Wu, Junge Zhang
-
Publication number: 20240082346Abstract: The present invention provides a composition comprising an antiviral agent and a C—X—C chemokine receptor type 4 (CXCR4) antagonist, and methods for using the same. Compositions and methods of the invention can be used to treat viral infection, immune disorders (e.g., rheumatoid arthritis), pulmonary fibrosis, or any other clinical condition associated with abnormal expression (e.g., overexpression and/or upregulation) of CXCR4. Compounds of the invention can also be used in stem cell therapeutics.Type: ApplicationFiled: August 21, 2023Publication date: March 14, 2024Applicant: Mainline Biosciences (Shanghai) Co., Ltd.Inventors: Junge Zhang, Liang Zeng Yan
-
Patent number: 11883501Abstract: The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.Type: GrantFiled: September 20, 2021Date of Patent: January 30, 2024Assignee: Mainline Biosciences (Shanghai) Co., Ltd.Inventors: Junge Zhang, Liang Zeng Yan
-
Patent number: 11771736Abstract: The present invention provides a composition comprising a therapeutic agent and a C-X-C chemokine receptor type 4 (CXCR4) antagonist, and methods for using the same. Compositions and methods of the invention can be used to treat cancer, viral infection, immune disorders (e.g., rheumatoid arthritis), pulmonary fibrosis, or any other clinical condition associated with abnormal expression (e.g., overexpression and/or upregulation) of CXCR4. Compounds of the invention can also be used in stem cell therapeutics.Type: GrantFiled: December 21, 2018Date of Patent: October 3, 2023Assignee: Mainline Biosciences (Shanghai) Co., Ltd.Inventors: Junge Zhang, Liang Zeng Yan
-
Publication number: 20220389635Abstract: Provided are a balance assembly and a household appliance. The balance assembly is applied in the household appliance. The balance assembly includes a balancing ring, a balancer, an identification member and a first detection member. The balancing ring has a chamber defined therein. The balancer is movably arranged in the chamber and includes a rotating member and a driving member. The driving member is connected to the rotating member and configured to drive the rotating member to rotate to drive a movement of the balancer within the chamber. A relative movement between the first detection member and the identification member occurs during the movement of the balancer. The first detection member is to detect a number of times of the identification member passing through the first detection member. The number of times of the identification member passing through the first detection member is related to a position of the balancer.Type: ApplicationFiled: December 14, 2020Publication date: December 8, 2022Inventors: Junge ZHANG, Shuyun WU, Xinjian HUANG, Su ZHANG, Yuehui WANG
-
Publication number: 20220062433Abstract: The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.Type: ApplicationFiled: September 20, 2021Publication date: March 3, 2022Applicant: MAINLINE BIOSCIENCES, INC.Inventors: Junge Zhang, Liang Zeng Yan
-
Publication number: 20210393100Abstract: The present disclosure provides a movable electric device. The movable electric device includes a movable device body and a contact detection electrode. The movable device body has an electric drive means. The contact detection electrode is mounted on the movable device body. When the contact detection electrode _contacts diffusible dirt, a resistance, capacitance or impedance of the contact detection electrode varies.Type: ApplicationFiled: November 9, 2018Publication date: December 23, 2021Inventors: Pin YANG, Jiefeng CHENG, Xinjian HUANG, Shuyun WU, Junge ZHANG
-
Publication number: 20210389772Abstract: A movable electronic apparatus includes a mobile apparatus body, a contact-type detection apparatus and a control circuit. The mobile apparatus body is provided with an electrical drive assembly that drives the mobile apparatus body to move; the contact-type detection apparatus is mounted on the mobile apparatus body, and the contact-type detection apparatus is configured and when the contact-type detection apparatus contacts dispersed dirt, an electrical signal outputted by the contact-type detection apparatus changes; the control circuit is mounted on the mobile apparatus body, and the control circuit is configured to determine whether the dispersed dirt is detected according to the magnitude of the amount by which the electrical signal outputted by the contact-type detection apparatus changes, and to control the electrical drive assembly to drive the mobile apparatus body to execute a dirt dispersion prevention action when determined that dirt that may be dispersed is detected.Type: ApplicationFiled: November 9, 2018Publication date: December 16, 2021Inventors: Sungjin KIM, Pin YANG, Shuyun WU, Xinjian HUANG, Guangli XU, Junge ZHANG, Geng YU, Jiefeng CHENG
-
Patent number: 11123437Abstract: The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.Type: GrantFiled: January 26, 2020Date of Patent: September 21, 2021Assignee: Mainline Biosciences, Inc.Inventors: Junge Zhang, Liang Zeng Yan
-
Publication number: 20210205407Abstract: The present invention provides a composition comprising a therapeutic agent and a C-X-C chemokine receptor type 4 (CXCR4) antagonist, and methods for using the same. Compositions and methods of the invention can be used to treat cancer, viral infection, immune disorders (e.g., rheumatoid arthritis), pulmonary fibrosis, or any other clinical condition associated with abnormal expression (e.g., overexpression and/or upregulation) of CXCR4. Compounds of the invention can also be used in stem cell therapeutics.Type: ApplicationFiled: December 21, 2018Publication date: July 8, 2021Applicant: Mainline Biosciences LLCInventors: Junge Zhang, Liang Zeng Yan
-
Patent number: 10870681Abstract: The present invention provides method treating a subject suffering from a clinical condition associated with CXCR4 activity, said method comprising administering to a subject in need of such a treatment a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein a is 0 or 1; AA1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, or optionally substituted homocysteine; AA2 along with the sulfur atom that is attached thereto is cysteine or homocysteine; Ar1 is an optionally substituted aryl; X1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); X2 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr), a D-isomer thereof, or absent; X3 is Gly or absent; X4 is Phe, 2Nal, 1Nal, or absent; X5 is Gly or absent; R2 is —OR4 or —NHR5; R4 is H or alkyl; and R5 is H, alkyl, optionally substituted aryl, optionally substituted aralkyl.Type: GrantFiled: June 4, 2019Date of Patent: December 22, 2020Assignee: MAINLINE BIOSCIENCES LLCInventors: Junge Zhang, Liang Zeng Yan
-
Publication number: 20200155697Abstract: The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.Type: ApplicationFiled: January 26, 2020Publication date: May 21, 2020Applicant: Mainline BiosciencesInventors: Junge Zhang, Liang Zeng Yan
-
Patent number: 10639379Abstract: The present invention provides a compound that can be used for targeted drug delivery, imaging a patient, or diagnosing a subject for a clinical condition which is believed to be associated with overexpression and/or upregulation of CXCR4. In particular, the present invention provides a high affinity CXCR4 selective binding ligand peptide conjugate (PC) of the Formula: P-(L-A)n (I) or a pharmaceutically acceptable salt thereof, and a method for using and producing the same. The high affinity CXCR4 selective binding ligand peptide conjugate (PC) of the invention is useful in diagnosing, treating or imaging a patient. In compound of Formula (I), n is an integer from 1 to the sum of (the total number of amino acid resides in P and the total number of side-chain functional group in the amino acid residue of P); each A is independently a diagnostic agent, a therapeutic agent, or an imaging agent; L is a linker or absent; and P is a high affinity CXCR4 selective binding peptidyl ligand.Type: GrantFiled: February 17, 2018Date of Patent: May 5, 2020Assignee: Mainline Biosciences LLCInventors: Junge Zhang, Liang Zeng Yan
-
Publication number: 20190309023Abstract: The present invention provides method treating a subject suffering from a clinical condition associated with CXCR4 activity, said method comprising administering to a subject in need of such a treatment a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein a is 0 or 1; AA1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, or optionally substituted homocysteine; AA2 along with the sulfur atom that is attached thereto is cysteine or homocysteine; Ar1 is an optionally substituted aryl; X1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); X2 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr), a D-isomer thereof, or absent; X3 is Gly or absent; X4 is Phe, 2Nal, 1Nal, or absent; X5 is Gly or absent; R2 is —OR4 or —NHR5; R4 is H or alkyl; and R5 is H, alkyl, optionally substituted aryl, optionally substituted aralkyl.Type: ApplicationFiled: June 4, 2019Publication date: October 10, 2019Applicant: Mainline BiosciencesInventors: Junge Zhang, Liang Zeng Yan
-
Publication number: 20190255185Abstract: The present invention provides a compound that can be used for targeted drug delivery, imaging a patient, or diagnosing a subject for a clinical condition which is believed to be associated with overexpression and/or upregulation of CXCR4. In particular, the present invention provides a high affinity CXCR4 selective binding ligand peptide conjugate (PC) of the Formula: P-(L-A)n (I) or a pharmaceutically acceptable salt thereof, and a method for using and producing the same. The high affinity CXCR4 selective binding ligand peptide conjugate (PC) of the invention is useful in diagnosing, treating or imaging a patient. In compound of Formula (I), n is an integer from 1 to the sum of (the total number of amino acid resides in P and the total number of side-chain functional group in the amino acid residue of P); each A is independently a diagnostic agent, a therapeutic agent, or an imaging agent; L is a linker or absent; and P is a high affinity CXCR4 selective binding peptidyl ligand.Type: ApplicationFiled: February 17, 2018Publication date: August 22, 2019Applicant: Mainline BiosciencesInventors: Junge Zhang, Liang Zeng Yan
-
Patent number: 10351601Abstract: The present invention provides compounds that are antagonists of CXCR4 and methods for using the same for treatment of a clinical condition associated with CXCR4 activation. In particular, compounds of the invention include cyclic peptides. Compounds of the invention can be used to treat a variety of clinical conditions, including but not limited to, cancers, pulmonary fibrosis, HIV infection, rheumatoid arthritis, and other immune disorders. In addition, compounds of the invention can also be used in stem cell therapy.Type: GrantFiled: September 5, 2017Date of Patent: July 16, 2019Assignee: Mainline BiosciencesInventors: Junge Zhang, Liang Zeng Yan
-
Publication number: 20180066021Abstract: The present invention provides compounds that are antagonists of CXCR4 and methods for using the same for treatment of a clinical condition associated with CXCR4 activation. In particular, compounds of the invention include cyclic peptides. Compounds of the invention can be used to treat a variety of clinical conditions, including but not limited to, cancers, pulmonary fibrosis, HIV infection, rheumatoid arthritis, and other immune disorders. In addition, compounds of the invention can also be used in stem cell therapy.Type: ApplicationFiled: September 5, 2017Publication date: March 8, 2018Applicant: Mainline BiosciencesInventors: Junge Zhang, Liang Zeng Yan